[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thyroid-nodules\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thyroid-nodules":226},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,37,57,84,104,128,152,181,203],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":20,"conditions":21,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":36},"100610378",false,"NCT07226804","Nanosecond Pulsed Field Ablation in the Management of Benign Thyroid Nodules","Eligibility Criteria\n\n* Scheduled to undergo ultrasound guided nsPFA as standard of care\n* Age 18 to 80 years.\n* Capable of providing independent consent.\n* Presence of biopsy-confirmed benign thyroid nodule , defined as one of the following:\n\n  * Benign FNA X 2 or\n  * Benign US guided FNA X 1 + benign thyroid nodule ultrasound appearance (TI-RADS 2) or\n  * Benign FNA X 1 and radiographic\u002Flaboratory evidence of functional nature\n* Nodule measuring \\>2cm in greatest dimension\n* Presence of compressive symptoms reasonably attributable to thyroid nodule (i.e. pressure sensation, dysphagia, dysphonia, respiratory distress)\n* No abnormal cervical lymph nodes during screening visit .\n\nExclusion Criteria\n\n* Age \\\u003C18\n* Patients considered unsuitable for nsPFA by the treating physician","ALL","18 Years",{"count":17,"type":18},30,"ESTIMATED","OBSERVATIONAL","To observe the outcomes of nsPFA therapy to treat benign thyroid nodules.",[22,23],"Thyroid Nodules","Pulsed Field Ablation","RECRUITING","2026-05-29",{"date":27,"type":28},"2026-06-01","ACTUAL",{"date":30,"type":28},"2025-11-14",{"date":32,"type":18},"2030-08-31",{"name":34,"class":35},"M.D. Anderson Cancer Center","OTHER",1,{"id":38,"slug":4,"hasResults":10,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":4,"eligibilityCriteria":42,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":43,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":45,"conditions":46,"keywords":47,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":36},"100453805","NCT05189314","RFA of Benign Thyroid Nodules: Clinical Outcomes and Quality of Life Study","Clinical Outcomes and Quality of Life Measures After Surgical Resection and Radiofrequency Ablation of Benign Thyroid Nodules","Inclusion Criteria:\n\n* Adult patients \\>\u002F=18 years old with benign thyroid nodules\n\nExclusion Criteria:\n\n* cardiac arrhythmia\n* pregnancy",{"count":44,"type":18},100,"The purpose of this observational research is to evaluate and compare clinical outcomes after treatment for symptomatic benign multinodular goiter (MNG) patients. This is a data collection study in which we ask participants to give access to information generated before and after treatment of their condition.",[22],[48],"Radiofrequency Ablation","2026-05-27",{"date":25,"type":28},{"date":52,"type":28},"2019-08-30",{"date":54,"type":18},"2028-08",{"name":56,"class":35},"Columbia University",{"id":58,"slug":4,"hasResults":10,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":4},"100630508","NCT07488585","A Novel Ultrasound Probe for Thyroid Imaging and Machine Learning","A Novel Ultrasound Probe for Thyroid Imaging and Machine Learning: A Pilot Study","THYMAL 01","Inclusion Criteria:\n\n* Participants must be ≥ 18 years of age\n* Able and willing to sign informed consent\n* Known thyroid nodule demonstrated on a prior thyroid US and is undergoing active surveillance of the nodule with serial USs\n\nExclusion Criteria:\n\n* Unable to lay flat for 15 minutes\n* Active neck wounds, dressings, or skin conditions that would interfere with neck US (e.g., preclude transducer placement)\n* Cervical spine or back disease that would prevent neck extension and would hinder the ability to obtain accurate thyroid US images\n* Previous thyroid surgeries, radiation of face and neck\n* Known inflammatory thyroid diseases or thyroiditis (e.g., Graves, Hashimoto)",{"count":17,"type":18},"INTERVENTIONAL",[67],"NA","The objective of the THYMAL 01 pilot study is to evaluate the Sound Blade Imaging System in subjects with benign thyroid nodules undergoing standard-of-care ultrasound imaging.",[22,70],"Thyroid Abnormalities",[72],"Thyroid Nodule","NOT_YET_RECRUITING","2026-04-03",{"date":76,"type":28},"2026-04-07",{"date":78,"type":18},"2026-05-31",{"date":80,"type":18},"2027-09",{"name":82,"class":83},"Sound Blade Medical Inc.","INDUSTRY",{"id":85,"slug":4,"hasResults":10,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":65,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":36},"100542290","NCT06340945","The Outcomes of Ultrasound-guided Thermal Ablation for Benign Thyroid Nodules","The Clinical Outcomes and Artificial Intelligence Prediction Model of Ultrasound-guided Thermal Ablation for the Treatment of Benign Thyroid Nodules：A Multicenter Prospective Study","Inclusion Criteria:\n\n* \\[1\\]confirmation of benign nodule status on two separate fine- needle aspiration (FNA) or core-needle biopsy (CNB) \\[2\\]no suspicious malignant features on ultrasound examination \\[3\\]report of cosmetic and\u002F or symptomatic problems or concern of nodules growing rapidly or malignant transformation \\[4\\]refusal or ineligibility for surgery \\[5\\]follow-up time ≥6months\n\nExclusion Criteria:\n\n1. follicular neoplasm or malignancy findings on biopsy\n2. nodules with benign result on biopsy had suspicious of malignancy in US, including marked hypoechoic, ill-defined margins, taller-than-wide shape or microcalcifications\n3. patients with cystic nodules\n4. patients with contra-lateral vocal cord par- alysis\n5. previous radiation to the head and neck\n6. ; follow- up time less than 6 months",{"count":91,"type":18},1500,[67],"1. To evaluate the clinical outcomes of ultrasound-guided thermal ablationfor the treatment of benign thyroid nodules;\n2. To develop and validate a artificial intelligence model to predict the outcomes of ultrasound-guided thermal ablation in the treatment of benign thyroid nodules",[22],"2026-03-18",{"date":97,"type":28},"2026-03-19",{"date":99,"type":28},"2024-04-01",{"date":101,"type":18},"2029-12-31",{"name":103,"class":35},"Chinese PLA General Hospital",{"id":105,"slug":4,"hasResults":10,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":65,"phases":113,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":126,"locationsCount":36},"100620666","NCT07360587","Thyroid Artery Embolization for the Treatment of Compressive Goiters.","Thyroid Artery Embolization for the Treatment of Compressive Goiters: a Prospective Cohort Study.","TAE","Inclusion Criteria:\n\n* Patient with compressive symptoms or significant tracheal or oesophageal compression at risk of causing symptoms attributed to a goiter AND\n* Ineligible for surgery\u002Fablative treatments or preference for TAE over other treatments AND\n* TiRADS category 1, 2, 3 or 4 AND\n* Bethesda categories I or III on 2 different biopsies OR Bethesda II on one biopsy AND\n* Patient at least 18 years old.\n\nExclusion Criteria:\n\n* Comorbidities precluding endovascular procedure OR\n* TiRADS category 5 OR\n* Bethesda categories IV, V, VI on biopsy OR\n* Refusal of the patient to participate OR\n* Uncontrolled severe hyperthyroidism OR\n* Minor patient.",{"count":112,"type":18},20,[67],"Very few studies have investigated TAE as a treatment for goiter with compressive symptoms. What is the efficacy and safety of TAE for the treatment of compressive goiters in a population ineligible for or refusing standard therapy? This is a prospective interventional cohort study that will allow us to standardize imaging by improving quality data collection and fellow-up to assess the efficacy of TAE for compressive symptoms of nodular goiters. Not only to corroborate current emerging results but clearly define the expected results for this technique.",[22],[117,118,119],"Goiter","Thyroid Artery Embolization","thyroid nodule","2026-01-16",{"date":122,"type":28},"2026-01-22",{"date":124,"type":18},"2026-01-31",{"date":101,"type":18},{"name":127,"class":35},"Université de Sherbrooke",{"id":129,"slug":4,"hasResults":10,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":65,"phases":137,"briefSummary":139,"conditions":140,"keywords":141,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":36},"100619096","NCT07340177","Xiaojin Pill\u002FNeixiao Luoli Pill for the Treatment of Thyroid Nodules","An Open-label, Multicenter, Randomized Controlled Clinical Trial of Xiaojin Pill\u002FNeixiao Luoli Pill for the Treatment of Thyroid Nodules","Inclusion Criteria:\n\n* Adults aged 18 to 65 years.\n* Diagnosed with single or multiple thyroid nodules confirmed by high-resolution ultrasound, with at least one measurable nodule.\n* Thyroid nodules meeting one of the following criteria:\n* ACR TI-RADS category 3 with a maximum nodule diameter ≥ 1.0 cm; or\n* ACR TI-RADS category 4 or 5 nodules evaluated by fine-needle aspiration and assessed as low-risk papillary thyroid carcinoma, suitable for active surveillance, with patient consent.\n* Normal thyroid function at baseline, defined as thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), and free thyroxine (FT4) within the reference range.\n* Traditional Chinese medicine (TCM) syndrome differentiation consistent with liver qi stagnation, blood stasis, or phlegm-dampness syndrome.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Thyroid nodules confirmed as malignant or follicular neoplasms requiring surgical intervention, or assessed by the investigator as unsuitable for active surveillance.\n* Presence of hyperthyroidism or hypothyroidism, defined as abnormal TSH, FT3, or FT4 levels.\n* History of severe cardiovascular, hepatic, renal, hematologic, psychiatric, autoimmune diseases, or other malignancies.\n* Pregnant or breastfeeding women, or women planning pregnancy during the study period.\n* Known allergy or hypersensitivity to Xiaojin Pill, Neixiao Luoli Pill, placebo components, or any ingredients of the study medications.\n* Receipt of thyroid-related surgery, radiofrequency ablation, laser ablation, radioactive iodine therapy, or other treatments that may affect thyroid nodules within 3 months prior to enrollment.\n* Current use of medications known to affect thyroid function or thyroid nodules, such as amiodarone or lithium.\n* Poor treatment compliance or inability to complete follow-up as judged by the investigator.\n* Participation in another clinical trial during the study period.","65 Years",{"count":136,"type":18},108,[138],"PHASE4","The goal of this clinical trial is to learn whether Xiaojin Pill or Neixiao Luoli Pill can safely treat thyroid nodules in adults aged 18 to 65 years with benign or low-risk thyroid nodules. The main questions it aims to answer are:\n\n* Does treatment with Xiaojin Pill or Neixiao Luoli Pill lower the size of thyroid nodules compared with lifestyle intervention alone?\n* Do Xiaojin Pill or Neixiao Luoli Pill improve thyroid nodule-related symptoms and ultrasound findings while remaining safe to use?\n\nResearchers will compare lifestyle intervention plus Xiaojin Pill, lifestyle intervention plus Neixiao Luoli Pill, and lifestyle intervention alone to see if adding Xiaojin Pill or Neixiao Luoli Pill works better than lifestyle intervention by itself.\n\nParticipants will:\n\n* Be randomly assigned to one of the three study groups;\n* Receive lifestyle intervention guidance throughout the study;\n* Take Xiaojin Pill, Neixiao Luoli Pill, or no study medicine for 12 weeks, depending on their group;\n* Attend follow-up visits that include thyroid ultrasound exams, blood tests to check thyroid function and safety, and symptom assessments.",[22],[142],"Thyroid nodule","2026-01-05",{"date":145,"type":28},"2026-01-14",{"date":147,"type":18},"2026-03",{"date":149,"type":18},"2027-06",{"name":151,"class":35},"Zhejiang Provincial People's Hospital",{"id":153,"slug":4,"hasResults":10,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":158,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":65,"phases":161,"briefSummary":162,"conditions":163,"keywords":168,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":36},"100615966","NCT07299474","Efficacy of Lavender Aromatherapy on Anxiety and Pain Reduction During Awake Otolaryngologic Procedures","Efficacy Of Lavender Aromatherapy on Anxiety and Pain Reduction During Awake Otolaryngologic Procedures","Inclusion Criteria:\n\n* Adults ≥18 years old undergoing awake otolaryngologic procedures in the outpatient clinic\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Hypersensitivity to fragrances\n* Taking systemic NSAIDs or other systemic pain-relieving medications within 48 hours\n* Taking anxiolytics, hypnotics, sedating antihistamines, antidepressants on regular basis within 4 weeks\n* Pregnant or breastfeeding\n* Participation in another clinical research study within the prior 30 days",true,{"count":160,"type":18},184,[67],"The purpose of this study is to evaluate the efficacy of lavender aromatherapy in adult patients undergoing awake otolaryngologic procedures in the outpatient clinic setting. The main questions it aims to answer are:\n\n* Does lavender aromatherapy help reduce anxiety and\u002For pain, and improve patient comfort during awake otolaryngologic procedures in the clinic?\n* Do patients subjectively find aromatherapy relaxing and\u002For beneficial during the procedure?\n\nResearchers will compare lavender aromatherapy to placebo (an odorless liquid) to see if lavender aromatherapy helps improve patient comfort during their awake procedure\n\nParticipants will:\n\n* Have their scheduled procedure performed with lavender aromatherapy or placebo during the duration of the procedure\n* Take a short, less than 1 minute questionnaire both before and after the procedure, describing their levels of anxiety, pain and subjective impressions of the aromatherapy",[164,165,166,22,167],"Inferior Turbinate Hypertrophy","Chronic Rhinosinusitis (CRS)","Rhinitis, Vasomotor","Vocal Fold Immobility",[169,170,171],"Aromatherapy","Otolaryngology","Awake procedure","2025-12-09",{"date":174,"type":28},"2025-12-23",{"date":176,"type":18},"2025-12",{"date":178,"type":18},"2028-01",{"name":180,"class":35},"Cedars-Sinai Medical Center",{"id":182,"slug":4,"hasResults":10,"nctId":183,"briefTitle":184,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":65,"phases":189,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":36},"100495115","NCT05726981","Ultrasound and Cytological Evaluation 3 Years After Radiofrequency Thermal Ablation of Benign Thyroid Nodules : a Prospective Exploratory Cohort of 180 Nodules","CYTOTHYRAF","Inclusion Criteria:\n\n1. Patients \\> 18 years old\n2. Carrier of a benign thyroid nodule that has undergone radiofrequency thermoablation 36 months previously ± 12 months +\u002F- 1 month, whether the nodule is stable, progressing or decreasing in volume during the screening period and\u002For on the day of inclusion.\n3. Obtaining written informed consent\n4. Affiliation to a social security system (excluding AME)\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women\n2. Previous alcohol use\n3. Patients on anti-vitamin K anticoagulants\n4. Patients on direct oral anticoagulants\n5. Persons deprived of liberty by judicial or administrative decision\n6. Persons under forced psychiatric care\n7. Persons admitted to a health or social institution for purposes other than research\n8. Persons of full age who are under legal protection (guardianship or curatorship)\n9. Persons unable to express their consent\n10. Persons under a legal protection measure (there can be no derogation for this category)",{"count":188,"type":18},180,[67],"There is no scientific data on post-thermal ablation cytological aspects, but treated nodules that grow back significantly after a procedure justify a new cytology in order not to ignore a neoplastic process.\n\nThe EU-TIRADS classification usually used to stratify the risk of cancer (and to justify a fine needle aspiration biopsy) of thyroid nodules is not validated for nodules treated by thermal ablation (TA) (post-RF nodules). However, these nodules often acquire ultrasound criteria of suspicion making it necessary to develop an ultrasound stratification of the risk of malignancy specific to nodules treated by TA.\n\nThe objective of this work is to describe the ultrasound and cytological aspects of these treated nodules by performing a systematic assessment at 3 years after thermal ablation including systematic neck ultrasound and fine needle aspiration biopsy. Thus, an ultrasound and cytological atlas (Bethesda classification 2017) of nodules treated by thermal ablation will be constituted.",[192,193,22],"Thermal Ablation","Fine Needle Aspiration Biopsy","2025-08-26",{"date":196,"type":28},"2025-09-03",{"date":198,"type":28},"2023-06-29",{"date":200,"type":18},"2026-04",{"name":202,"class":35},"Assistance Publique - Hôpitaux de Paris",{"id":204,"slug":4,"hasResults":10,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":209,"enrollmentInfo":4,"targetDuration":4,"studyType":210,"phases":4,"briefSummary":211,"conditions":212,"keywords":213,"overallStatus":216,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":4},"100280978","NCT02937467","The Multi-Center Study of Shear Wave Elastography on Thyroid Nodules","Evaluation of Shear Wave Elastography in the Diagnosis and Management of Thyroid Nodules in Chinese Population: A Prospective, Multicenter Study","Inclusion Criteria\n\n1. the size of the lesion is between 0.5～4cm\n2. the solid components in the lesion\\>50%；\n3. all patients perform FNA or surgery in one month after SWE examination\n\nExclusion Criteria:\n\n1. patients who are unwilling or unable to provide informed consent\n2. Woman who is pregnant or breastfeeding;\n3. Thyroid nodules with calcified which is beyond 1\u002F2 diameter of lesion\n4. patients who have history of surgery、FNA or thermal ablation in ipsilateral thyroid\n5. patients who have serious cardiopulmonary diseases","80 Years","EXPANDED_ACCESS","The incidence rates of thyroid cancers have increased in the past decade. Additionally, up to 68% of people have thyroid nodules. Consequently, a precise evaluation of thyroid nodules is very important and can avoid unnecessary biopsy of benign nodules. Shear wave elastography(SWE), a novel ultrasound-based elastographic method, is a new real-time, quantitative, operator-independent, and reproducible technique. Briefly, shear wave elastography uses a radiation force produced by an ultrasonic beam to stress tissues and ultrafast sonographic tracking techniques to measure the speed of shear waves. Based on the Young modulus formula, tissue elasticity can be derived from the shear wave propagation speed, and a real-time color-coded elastogram can be displayed, showing softer tissue in blue and stiffer tissue in red.\n\nThere are lots of research confirmed that SWE has a certain value in the diagnosis of thyroid carcinoma. These studies include prospective studies and retrospective studies, but both belong to a single center study. It has not been applied to the study of the multicenter of thyroid disease.\n\nThe main purpose of the study is to assess the performance of SWE for identification of benign and malignant thyroid nodules and calculate the optimal cutoff value for each parameter in multicenter study; the secondary purpose is to evaluate the application value of SWE for uncertain nodules by FNA.",[22],[214,215],"SWE","diagnosis","AVAILABLE","2016-10-15",{"date":219,"type":18},"2016-10-18",{"date":221,"type":4},"2016-12",{"date":223,"type":18},"2018-12",{"name":225,"class":35},"Peking University Cancer Hospital & Institute",""]